Intraperitoneal Tramadol Versus Dexmedetomedine for Analgesia After Abdominal Laparoscopic Cancer Surgeries

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (112 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-05-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: ckdadministrationcardiacmultiplepilot
  Phrases that lowered it: patientsanalgesicbupivacainewith historyintraperitoneal
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 29 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 17.4% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Phase: 2/3 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Drug's FAERS reports marked serious: 93.2% (raises risk) · Drug's FDA history
• Sponsor's past trials: 24 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Intra-Peritoneal Local Anaesthesia After Cytoreductive Surgery NCT02256228 · started 2014 · scored riskier than 13% of active trials completed
• Comparing Liposomal Bupivacaine Versus Standard Bupivacaine in Colorectal Surgery NCT03702621 · started 2018 · scored riskier than 72% of active trials completed
• Postoperative Analgesic Effectiveness of Bupivacaine With and Without Dexmedetomidine in Patients With Abdominal Surgery NCT06531603 · started 2022 · scored riskier than 36% of active trials completed
• The Effect of Intraperitoneal Instillation of Bupivacaine on Postoperative Pain After Surgical Laparoscopy NCT06616441 · started 2023 · scored riskier than 15% of active trials completed
• Perioperative Epidural Versus Intravenous Local Anesthetic Infusion in Open Upper Abdominal Surgery NCT03005171 · started 2017 · scored riskier than 8% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.